SEC Form 4/A · accession 0001144204-15-046719
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Barbara Gayle Duncan
Director
Period of report
Jul 22, 2015
Accepted (ET)
Aug 6, 2015 · 8:30 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Award (Right to buy)F1,F2 | $8.09 | Jul 22, 2015 | A | 40,000 | A | — | Jul 22, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1This Form 4 is an amendment of the Form 4 filed on July 23, 2015, and corrects the number of securities and date exercisable of the reported stock option award. The terms of the reported stock option award were correctly reported in the Form 8-K filed with the SEC on June 10, 2015 in connection with Ms. Duncan's appointment as a Director.
- F2The shares will be exercisable over a three-year period, with 13,333 exercisable on July 22, 2016, an additional 13,333 exercisable on July 22, 2017, and an additional 13,334 on July 22, 2018.